30
2020-09
Kintor Pharmaceutical Signs Strategic Cooperation Agreement with MabPlex
On 30 September 2020, Kintor Pharmaceutical Limited announced that Kintor Pharmaceutical entered into a strategic cooperation agreement with MabPlex International Ltd. , pursuant to which both parties will carry out all-round cooperation on the research and development and production in biological macromolecular drugs.
17
2020-09
Acne Drug KX-826 Gel Approved for Clinical Trials in China
On 17 September 2020, Kintor Pharmaceutical Limited is pleased to announce that it has received clinical trial approval from the National Medical Products Administration for the gel dosage form of KX-826 for the treatment of acne and androgenetic alopecia.
11
2020-09
Among them, Kintor Pharmaceutical Limited was listed on the TOP100 Chemical Drug Research and Development Strength Rankings in China for 2020, and was also selected to enter the most important sub-list "TOP100 Chemical Pharmaceutical Research and Development Strength Rankings in China for 2020".
01
2020-09
Kintor Pharmaceutical Enters Loncar China BioPharma Index after 100 Days of Listing in HK
In August 2020, the Loncar China BioPharma Index underwent its six-monthly adjustments and restructuring, adding 14 biopharmaceutical companies, including Kintor Pharmaceutical Limited (stock code: 9939.HK).
01
2020-09
Three Parties Jointly Build A Precise Cancer Treatment Platform
(September 1, 2020, Hong Kong) Kintor Pharmaceutical Limited (stock code: 9939, hereinafter referred to as “Kintor Pharmaceutical” or the “Company”) signed a strategic cooperation framework agreement with Suzhou GloriousMed Biomedical Group Co., Ltd. (hereinafter referred to as “GloriousMed”) and HM Shuke (Beijing) Medical Technology Co., Ltd. (hereinafter referred to as “HM Healthcare”), under which the three parties will create a patient-centered, integrated precise cancer treatment platform.
01
2020-09
New Start For New Journey! Kintor Relocated To Suzhou R&D Center And Industrialization Base
On 28 August 2020, Kintor Pharmaceutical Limited (Stock Code: 9939.HK, hereinafter referred to as the “Kintor Pharmaceutical”), officially moved to Suzhou self-established R&D center and industrialization base, symbolising a new development chapter for Kintor Pharmaceutical.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn